{
  "docId": "019de077-5130-7668-92cb-6c77396e6bd2",
  "docSlug": "e021a2de9332664c5094197b4bc248cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 157 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 98,
  "pageCount": 132,
  "prevPage": 97,
  "nextPage": 99,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Slide 98 of a presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5130-7668-92cb-6c77396e6bd2/98",
  "deckHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2",
  "deckJsonHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2.json",
  "deckAnchorHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2#slide-98",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.038,
        "y": 0.192
      },
      "kind": "table",
      "text": "Trial: Phase III TILIA NCT05624450; Population: Adults hospitalised for viral lung infection requiring supplemental oxygen; Patients: 2870; Design: Randomised, double-blind, placebo-controlled, parallel group; Endpoints: Primary endpoint: progression to death or to invasive mechanical ventilation/extracorporeal membrane oxygenation; Status: FPCD: Q4 2022 Data anticipated: >2025",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75efdf5b-53b6-4d0c-9748-9007ba502fe7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.496,
        "x": 0.035,
        "y": 0.045
      },
      "kind": "title",
      "text": "tozorakimab (IL-33 ligand mAb)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1148109e-ceaa-4f83-849d-f76fd1a21a84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.035,
        "y": 0.115
      },
      "kind": "title",
      "text": "Severe viral LRTD, asthma",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed10ed8b-43b0-4216-9be9-b51bf0367272",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "2865bb74-bb4e-4268-89c4-2bda2302b6b3",
      "evidence": "components: table/data: Trial: Phase III TILIA NCT05624450; Population: Adults hospitalised for viral lung infection requiring supplemental oxygen; Patients: 2870; Design: Randomised, double-blind, placebo-controlled, parallel group",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 6,
      "beatId": "0c127c3c-ea10-450c-b057-64b7f7a0f03c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Detailed overview of AstraZeneca's pipeline and portfolio",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}